

26 August 2025



**CRISM Therapeutics Corporation**  
("CRISM", "CRISM Therapeutics" or the "Company")

**Result of AGM**

CRISM Therapeutics (AIM: CRTX) the innovative UK drug delivery company focused on the localised delivery of chemotherapy drugs, is pleased to confirm that at the Company's Annual General Meeting held earlier today, all resolutions were duly passed. Full details of the resolutions are set out in the Notice of Annual General Meeting dated 4 August 2025 and available on the Company's website at: <https://www.crismltherapeutics.com/documents-and-notices>

The votes cast were as follows:

Resolution	Votes for	Votes for %	Votes against	Votes against %	Abstentions
1	5,094,571	100.00%	-	-	62
2	5,094,049	99.99%	510	0.01%	74
3	5,094,571	100.00%	-	-	62
4	5,094,571	100.00%	-	-	62
5	5,094,571	100.00%	-	-	62
6	5,094,559	100.00%	-	-	74
7	5,094,571	100.00%	-	-	62
8	5,094,049	99.99%	572	0.01%	12
9	5,094,049	99.99%	572	0.01%	12
10	5,094,049	99.99%	572	0.01%	12
11	5,094,213	99.99%	346	0.01%	74
12	5,094,213	99.99%	408	0.01%	12
13	5,094,213	99.99%	408	0.01%	12

-Ends-

**Enquiries:**

**Company**  
**CRISM Therapeutics Corporation**

Andrew Webb, CEO  
Chris McConville, CSO  
via Burson Buchanan

**Nomad and Broker**  
**S.P. Angel Corporate Finance LLP**

Richard Morrison  
Vadim Alexandre  
Adam Cowl  
+44 (0) 20 3470 0470

**Financial PR**  
**Burson Buchanan**

Mark Court / Jamie Hooper  
CRISM@buchanancomms.co.uk  
+44 (0) 20 7466 5000

**About CRISM Therapeutics Corporation**

CRISM Therapeutics Corporation has developed an innovative drug delivery technology to improve the clinical performance of cancer treatments for solid tumours through the local delivery of chemotherapy drugs.

ChemoSeed, CRISM's lead product, can be implanted directly into the tumour or the resection margin following the removal of a tumour. This directs that therapeutic concentrations of chemotherapy drugs reach the deep-seated tumour tissue or cover the entire resection margin. In the case of treating glioblastoma, ChemoSeeds can be implanted during surgery thereby bypassing the blood brain barrier, which prevents other treatments from being able to reach the tumour and be effective.

For more information please visit: <https://www.crismltherapeutics.com/>

The Company's LEI is 213800XFW6MKVCHHPW88.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@seg.com](mailto:rns@seg.com) or visit [www.rns.com](http://www.rns.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

RAGUNRVRVRUWUAR